OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer - Related Studies

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

This study has been completed.

Study NCT00036647. Last updated on December 16, 2005. Information provided by OSI Pharmaceuticals

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Carcinoma, Non-Small-Cell Lung

2	Additional conditions recognized in this trial
		Carcinoma
		Lung Neoplasms

3	More general conditions related to this trial
		Lung Diseases
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Respiratory Tract Diseases
		Respiratory Tract Neoplasms
		Thoracic Neoplasms

4	Interventions listed in this trial
		Tarceva (erlotinib HCl, OSI-774 )

5	Additional drug interventions recognized in this trial
		Erlotinib

6	More general drug interventions related to this trial
		Enzyme Inhibitors
		Molecular Mechanisms of Pharmacological Action
		Pharmacologic Actions
		Protein Kinase Inhibitors

7	Sponsors listed in this trial
		OSI Pharmaceuticals
		National Cancer Institute of Canada